Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

Li Di; Per Artursson; Alex Avdeef; Gerhard F. Ecker; Bernard Faller; Holger Fischer; J. Brian Houston; Manfred Kansy; Edward H. Kerns; Stefanie D. Krämer; Hans Lennernäs; Kiyohiko Sugano

doi:10.1016/j.drudis.2012.03.015

Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

Li Di, Per Artursson, Alex Avdeef, Gerhard F. Ecker, Bernard Faller, Holger Fischer, J. Brian Houston, Manfred Kansy, Edward H. Kerns, Stefanie D. Krämer, Hans Lennernäs, Kiyohiko Sugano

Research output: Contribution to journal › Article › peer-review

Abstract

Evidence supporting the action of passive diffusion and carrier-mediated (CM) transport in drug bioavailability and disposition is discussed to refute the recently proposed theory that drug transport is CM-only and that new transporters will be discovered that possess transport characteristics ascribed to passive diffusion. Misconceptions and faulty speculations are addressed to provide reliable guidance on choosing appropriate tools for drug design and optimization. © 2012 Elsevier Ltd.

Original language	English
Pages (from-to)	905-912
Number of pages	7
Journal	Drug discovery today
Volume	17
Issue number	15-16
DOIs	https://doi.org/10.1016/j.drudis.2012.03.015
Publication status	Published - Aug 2012

Access to Document

10.1016/j.drudis.2012.03.015

Cite this

@article{582744a436594cf9996f693446569ecf,

title = "Evidence-based approach to assess passive diffusion and carrier-mediated drug transport",

abstract = "Evidence supporting the action of passive diffusion and carrier-mediated (CM) transport in drug bioavailability and disposition is discussed to refute the recently proposed theory that drug transport is CM-only and that new transporters will be discovered that possess transport characteristics ascribed to passive diffusion. Misconceptions and faulty speculations are addressed to provide reliable guidance on choosing appropriate tools for drug design and optimization. {\textcopyright} 2012 Elsevier Ltd.",

author = "Li Di and Per Artursson and Alex Avdeef and Ecker, {Gerhard F.} and Bernard Faller and Holger Fischer and Houston, {J. Brian} and Manfred Kansy and Kerns, {Edward H.} and Kr{\"a}mer, {Stefanie D.} and Hans Lennern{\"a}s and Kiyohiko Sugano",

year = "2012",

month = aug,

doi = "10.1016/j.drudis.2012.03.015",

language = "English",

volume = "17",

pages = "905--912",

journal = "Drug discovery today",

issn = "1359-6446",

publisher = "Elsevier BV",

number = "15-16",

}

TY - JOUR

T1 - Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

AU - Di, Li

AU - Artursson, Per

AU - Avdeef, Alex

AU - Ecker, Gerhard F.

AU - Faller, Bernard

AU - Fischer, Holger

AU - Houston, J. Brian

AU - Kansy, Manfred

AU - Kerns, Edward H.

AU - Krämer, Stefanie D.

AU - Lennernäs, Hans

AU - Sugano, Kiyohiko

PY - 2012/8

Y1 - 2012/8

N2 - Evidence supporting the action of passive diffusion and carrier-mediated (CM) transport in drug bioavailability and disposition is discussed to refute the recently proposed theory that drug transport is CM-only and that new transporters will be discovered that possess transport characteristics ascribed to passive diffusion. Misconceptions and faulty speculations are addressed to provide reliable guidance on choosing appropriate tools for drug design and optimization. © 2012 Elsevier Ltd.

AB - Evidence supporting the action of passive diffusion and carrier-mediated (CM) transport in drug bioavailability and disposition is discussed to refute the recently proposed theory that drug transport is CM-only and that new transporters will be discovered that possess transport characteristics ascribed to passive diffusion. Misconceptions and faulty speculations are addressed to provide reliable guidance on choosing appropriate tools for drug design and optimization. © 2012 Elsevier Ltd.

U2 - 10.1016/j.drudis.2012.03.015

DO - 10.1016/j.drudis.2012.03.015

M3 - Article

SN - 1359-6446

VL - 17

SP - 905

EP - 912

JO - Drug discovery today

JF - Drug discovery today

IS - 15-16

ER -

Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

Abstract

Access to Document

Fingerprint

Cite this